AR128917A1 - Inhibidores de malt-1 de tiazolo[5,4-b]piridina - Google Patents
Inhibidores de malt-1 de tiazolo[5,4-b]piridinaInfo
- Publication number
- AR128917A1 AR128917A1 ARP230100771A ARP230100771A AR128917A1 AR 128917 A1 AR128917 A1 AR 128917A1 AR P230100771 A ARP230100771 A AR P230100771A AR P230100771 A ARP230100771 A AR P230100771A AR 128917 A1 AR128917 A1 AR 128917A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- chf2
- alkyl
- compound
- Prior art date
Links
- 229940122339 MALT1 inhibitor Drugs 0.000 title 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 6
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación proporciona compuestos de la fórmula general (1) en donde R¹ᵃ, R¹ᵇ, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ y el anillo A tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos. Reivindicación 1: Un compuesto de la fórmula general (1), o una sal aceptable desde el punto de vista farmacéutico de este, en donde: R¹ᵃ se selecciona del grupo que consiste en OCH₃ y CH₃; R¹ᵇ se selecciona del grupo que consiste en CH₃, CHF₂ y CF₃; R² se selecciona del grupo que consiste en H y F; R³ se selecciona del grupo que consiste en H y F; R⁴ se selecciona del grupo que consiste en CHF₂ y CF₃; R⁵ es C₁-C₄ alquilo; El anillo A es un anillo seleccionado del grupo que consiste en los restos de fórmula (a) y (b); R⁶ se selecciona del grupo que consiste en C₁-C₄ alquilo y C₁-C₄ hidroxialquilo; R⁷ se selecciona del grupo que consiste en H y C₁-C₄ alquilo; y R⁸ se selecciona del grupo que consiste en CHF₂ y CH₃. Reivindicación 21: Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de la fórmula (1) de acuerdo con la reivindicación 1, o una sal aceptable desde el punto de vista farmacéutico de este, en combinación con un portador aceptable desde el punto de vista farmacéutico. Reivindicación 23: Un método para sintetizar un compuesto de la fórmula (3A) de acuerdo con la reivindicación 1, al hacer reaccionar un compuesto de la fórmula (1G), con un compuesto de la fórmula (2G) en un solvente, en presencia de una base y un catalizador, para formar un compuesto de la fórmula (3A); en donde: R¹ᵃ se selecciona del grupo que consiste en OCH₃ y CH₃; R¹ᵇ se selecciona del grupo que consiste en CH₃, CHF₂ y CF₃; R² se selecciona del grupo que consiste en H y F; R³ se selecciona del grupo que consiste en H y F; R⁴ se selecciona del grupo que consiste en CHF₂ y CF₃; R⁵ es C₁-C₄ alquilo; El anillo A es un anillo seleccionado del grupo que consiste en los restos de fórmula (a) y (b); R⁶ se selecciona del grupo que consiste en C₁-C₄ alquilo y C₁-C₄ hidroxialquilo; R⁷ se selecciona del grupo que consiste en H y C₁-C₄ alquilo; y R⁸ se selecciona del grupo que consiste en CHF₂ y CH₃.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362302P | 2022-03-31 | 2022-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128917A1 true AR128917A1 (es) | 2024-06-26 |
Family
ID=86185307
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100771A AR128917A1 (es) | 2022-03-31 | 2023-03-29 | Inhibidores de malt-1 de tiazolo[5,4-b]piridina |
| ARP240102836A AR134155A2 (es) | 2022-03-31 | 2024-10-21 | Inhibidores de malt-1 de tiazolo[5,4-b]piridina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240102836A AR134155A2 (es) | 2022-03-31 | 2024-10-21 | Inhibidores de malt-1 de tiazolo[5,4-b]piridina |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11993613B2 (es) |
| EP (1) | EP4499650A1 (es) |
| JP (2) | JP7723030B2 (es) |
| KR (1) | KR20240168420A (es) |
| CN (1) | CN119855821A (es) |
| AR (2) | AR128917A1 (es) |
| AU (1) | AU2023243460A1 (es) |
| CA (1) | CA3246085A1 (es) |
| CO (1) | CO2024014618A2 (es) |
| IL (1) | IL316288A (es) |
| MX (1) | MX2024012018A (es) |
| TW (1) | TW202345806A (es) |
| WO (1) | WO2023192913A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| WO2025223516A1 (zh) * | 2024-04-24 | 2025-10-30 | 首药控股(北京)股份有限公司 | 一种抑制剂杂环化合物 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2496666A1 (fr) | 1980-12-22 | 1982-06-25 | Ici Pharma | Nouveaux derives de cephalosporine et composition pharmaceutique les contenant |
| US5851741A (en) | 1986-01-24 | 1998-12-22 | Fuji Photo Film Co., Ltd. | Method for the formation of color images |
| US5658889A (en) | 1989-01-24 | 1997-08-19 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
| US5646128A (en) | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5795977A (en) | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| US5726302A (en) | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
| EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| US6608058B2 (en) | 2000-04-17 | 2003-08-19 | Dong Wha Pharm. Ind. Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
| EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| AU2003293409A1 (en) | 2002-12-09 | 2004-06-30 | Karl K. Johe | Method for discovering neurogenic agents |
| SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| JP2006241089A (ja) | 2005-03-04 | 2006-09-14 | Astellas Pharma Inc | ピロロピリミジン誘導体またはその塩 |
| KR20070052207A (ko) | 2005-11-16 | 2007-05-21 | 주식회사 엘지생명과학 | 신규한 ｋｄｒ 억제제 |
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| MX2009006234A (es) | 2006-12-11 | 2009-06-22 | Wyeth Corp | Moduladores del canal de ion. |
| EA200900819A1 (ru) | 2006-12-22 | 2010-02-26 | Новартис Аг | Хиназолины для ингибирования pdk1 |
| JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
| JP5219594B2 (ja) | 2008-04-08 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルム及びフラットパネル表示装置 |
| US20100121052A1 (en) | 2008-06-20 | 2010-05-13 | Rama Jain | Novel compounds for treating proliferative diseases |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
| KR101699991B1 (ko) | 2009-02-11 | 2017-01-26 | 메르크 파텐트 게엠베하 | 신규의 아미노 아자헤테로시클릭 카르복사미드 |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| ES2632220T3 (es) | 2009-06-15 | 2017-09-11 | Rigel Pharmaceuticals, Inc. | Inhibidores de moléculas pequeñas de tirosina cinasa del bazo (SYK) |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| PT2730564T (pt) | 2010-11-19 | 2018-07-24 | Ligand Pharm Inc | Aminas heterocíclicas e suas utilizações |
| WO2012075232A1 (en) | 2010-12-04 | 2012-06-07 | Trevena, Inc. | Opioid receptor ligands and methods of using and making the same |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2013038308A1 (en) | 2011-09-15 | 2013-03-21 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS |
| ES2657955T3 (es) | 2012-04-17 | 2018-03-07 | Fujifilm Corporation | Compuesto heterocíclico que contiene nitrógeno o sal del mismo |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| EP2935261A1 (de) | 2012-12-20 | 2015-10-28 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydrochinoxalinone |
| WO2014146246A1 (en) | 2013-03-19 | 2014-09-25 | Merck Sharp & Dohme Corp. | Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors |
| WO2016027904A1 (ja) | 2014-08-22 | 2016-02-25 | 富士フイルム株式会社 | Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用 |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| US10351548B2 (en) | 2015-06-11 | 2019-07-16 | International Society For Drug Development S.R.L. | 2-oxo-1,2-dihydropyridine-3-carboxamide compounds and their use as inhibitors of PDK1 |
| EP3350158A4 (en) | 2015-09-16 | 2019-05-08 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| CA3000709A1 (en) | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| GB201603311D0 (en) | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| US10933068B2 (en) | 2016-05-26 | 2021-03-02 | Sonic Master Limited | Modulators of DUX4 for regulation of muscle function |
| CA3032334A1 (en) | 2016-07-29 | 2018-02-01 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018112077A1 (en) | 2016-12-13 | 2018-06-21 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| US11542233B2 (en) | 2016-12-23 | 2023-01-03 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| WO2018228475A1 (zh) | 2017-06-14 | 2018-12-20 | 正大天晴药业集团股份有限公司 | Syk抑制剂及其使用方法 |
| CN110709402B (zh) | 2017-06-15 | 2022-05-10 | 浙江海正药业股份有限公司 | 杂芳基并嘧啶酮类衍生物、其制备方法及其在医药上用途 |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| US10844044B2 (en) | 2018-06-14 | 2020-11-24 | Vanderbilt University | WDR5 inhibitors and modulators |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2020051571A1 (en) | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| EP3898630B1 (en) | 2018-12-17 | 2023-05-10 | F. Hoffmann-La Roche AG | Novel imidazopyrazine derivatives |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| EP4041230A4 (en) | 2019-10-07 | 2023-11-01 | D.E. Shaw Research, LLC | AROMATIC ARYLMETHYLENE COMPOUNDS AS BLOCKERS OF KV1.3 POTASSIUM AGITATOR CHANNELS |
| GB201914910D0 (en) | 2019-10-15 | 2019-11-27 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2021175200A1 (en) | 2020-03-02 | 2021-09-10 | Sironax Ltd | Ferroptosis inhibitors–diarylamine para-acetamides |
| CN113527291B (zh) | 2020-04-13 | 2025-07-22 | 广东东阳光药业股份有限公司 | Ret抑制剂、其药物组合物及其用途 |
| JP2023540270A (ja) | 2020-08-28 | 2023-09-22 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| EP4216946A4 (en) | 2020-09-23 | 2024-11-13 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| WO2022081995A1 (en) | 2020-10-16 | 2022-04-21 | Rheos Medicines, Inc. | Malt1 modulators and uses thereof |
| CN116916924A (zh) | 2020-10-16 | 2023-10-20 | 稀有生物科学股份有限公司 | Malt1调节剂及其用途 |
| TW202233580A (zh) | 2020-10-30 | 2022-09-01 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之調節劑 |
| GB202018412D0 (en) | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
-
2023
- 2023-02-17 TW TW112105833A patent/TW202345806A/zh unknown
- 2023-03-29 AU AU2023243460A patent/AU2023243460A1/en active Pending
- 2023-03-29 IL IL316288A patent/IL316288A/en unknown
- 2023-03-29 JP JP2023052720A patent/JP7723030B2/ja active Active
- 2023-03-29 CN CN202380037777.2A patent/CN119855821A/zh active Pending
- 2023-03-29 WO PCT/US2023/065111 patent/WO2023192913A1/en not_active Ceased
- 2023-03-29 KR KR1020247035987A patent/KR20240168420A/ko active Pending
- 2023-03-29 EP EP23719616.7A patent/EP4499650A1/en active Pending
- 2023-03-29 AR ARP230100771A patent/AR128917A1/es unknown
- 2023-03-29 CA CA3246085A patent/CA3246085A1/en active Pending
- 2023-03-30 US US18/192,810 patent/US11993613B2/en active Active
-
2024
- 2024-04-18 US US18/638,727 patent/US20250084099A1/en active Pending
- 2024-09-27 MX MX2024012018A patent/MX2024012018A/es unknown
- 2024-10-21 AR ARP240102836A patent/AR134155A2/es unknown
- 2024-10-25 CO CONC2024/0014618A patent/CO2024014618A2/es unknown
-
2025
- 2025-07-31 JP JP2025128083A patent/JP2025156455A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024014618A2 (es) | 2024-11-08 |
| WO2023192913A1 (en) | 2023-10-05 |
| US11993613B2 (en) | 2024-05-28 |
| AU2023243460A1 (en) | 2024-10-24 |
| TW202345806A (zh) | 2023-12-01 |
| JP7723030B2 (ja) | 2025-08-13 |
| US20250084099A1 (en) | 2025-03-13 |
| KR20240168420A (ko) | 2024-11-29 |
| US20230312601A1 (en) | 2023-10-05 |
| AR134155A2 (es) | 2025-12-10 |
| CA3246085A1 (en) | 2023-10-05 |
| JP2025156455A (ja) | 2025-10-14 |
| CN119855821A (zh) | 2025-04-18 |
| JP2023152927A (ja) | 2023-10-17 |
| MX2024012018A (es) | 2024-11-08 |
| IL316288A (en) | 2024-12-01 |
| EP4499650A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20212304A1 (es) | Inhibidores de il-17a imidazo[1,2-b]piridazin-2-il | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| AR128917A1 (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR127235A1 (es) | Pirazoloquinolinas inhibidoras de kras | |
| AR126351A1 (es) | Compuestos y sus sales inhibidores del inflamasoma nlrp3 | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| PE20240886A1 (es) | Compuestos espirociclicos | |
| AR117229A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
| AR129946A1 (es) | Inhibidores de cbl-b y métodos de uso de los mismos | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR124303A1 (es) | Inhibidores de irak4 | |
| ES2373172B1 (es) | Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales. | |
| AR029001A1 (es) | Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento | |
| AR124170A1 (es) | Nuevos derivados de indazol acetileno | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
| AR125312A1 (es) | Derivados heterocíclicos, composiciones farmacéuticas y su uso en el tratamiento o la mejora del cáncer | |
| AR127185A1 (es) | Compuestos de pirazolopiridina como inhibidores de tam | |
| AR129523A1 (es) | Inhibidores de cgas | |
| AR125363A1 (es) | Nuevos derivados de pirazolo[1,5-a]pirimidina como ligandos sigma | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 |